Clinical Trials Logo

Leukemia clinical trials

View clinical trials related to Leukemia.

Filter by:

NCT ID: NCT02016729 Completed - Cancer Clinical Trials

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

Start date: April 1, 2014
Phase: Phase 1
Study type: Interventional

Open-label, sequential dose escalation and expansion study of AMG 232 in subjects with acute myeloid leukemia.

NCT ID: NCT02015208 Completed - Clinical trials for Chronic Lymphocytic Leukemia

Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia

Start date: April 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine if Ruxolitinib, an inhibitor of cytokine-signaling, is effective in the treatment of patients with Chronic Lymphocytic Leukemia for whom conventional chemotherapy is either too toxic or ineffective.

NCT ID: NCT02014558 Completed - Clinical trials for Acute Myeloid Leukemia

Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Start date: October 9, 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this study was to assess the safety and tolerability, including the maximum tolerated dose, of gilteritinib in participants with relapsed or treatment-refractory acute myeloid leukemia (AML). This study also determined the pharmacokinetic (PK) parameters of gilteritinib.

NCT ID: NCT02013648 Completed - Clinical trials for Acute Myeloid Leukemia (AML)

Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycelâ„¢)

Start date: July 2014
Phase: Phase 3
Study type: Interventional

This is a randomized phase III open-label, multicenter trial evaluating standard induction therapy (daunorubicin [DNR] and cytarabine [Ara-C]) and consolidation therapy (high-dose cytarabine [HDAC]) with or without dasatinib in adult patients with newly diagnosed CBF-AML

NCT ID: NCT02013167 Terminated - Clinical trials for Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Start date: January 3, 2014
Phase: Phase 3
Study type: Interventional

The primary objective was to evaluate the effect of blinatumomab on overall survival when compared to standard of care (SOC) chemotherapy.

NCT ID: NCT02012699 Recruiting - Breast Cancer Clinical Trials

Integrated Cancer Repository for Cancer Research

iCaRe2
Start date: November 1, 2013
Phase:
Study type: Observational [Patient Registry]

The iCaRe2 is a multi-institutional resource created and maintained by the Fred & Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.

NCT ID: NCT02011945 Completed - Clinical trials for Chronic Myeloid Leukemia

A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia

Start date: February 7, 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find a dose of Nivolumab that can be safely added to Dasatinib in patients with Chronic Myeloid Leukemia.

NCT ID: NCT02010931 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients

Start date: September 2013
Phase:
Study type: Observational

A retrospective analysis of historical data looking at relapse free survival and overall survival rates in adult philadelphia negative B-pre-cursor acute lymphoblastic leukemia patients.

NCT ID: NCT02010645 Terminated - Leukemia Clinical Trials

Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)

Start date: March 2014
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if eltrombopag given in combination with decitabine can help to control advanced MDS. The safety of this study drug combination will also be studied.

NCT ID: NCT02007863 Completed - Leukemia Clinical Trials

Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia

Start date: August 2008
Phase: N/A
Study type: Interventional

Unrelated Cord Blood (UCB) transplant in children is a viable stem cell transplant modality for patients with leukemia and myelodysplasia. UCB is now considered "Standard Of Care" in cases where a suitable living bone marrow donor is not available. The survival of UCB is similar to Matched Unrelated Marrow Transplant. This study is considered "Research" since UCB is not a licensed product and requires investigational new drug (IND). THERE ARE NO SPECIFIC RESEARCH QUESTIONS IN THIS PROTOCOL. This protocol merely provides UCB as a stem cell treatment modality to pediatric patients who may require it after a conditioning regimen that excludes Total Body Irradiation.